Literature DB >> 12376615

Clinical applications of radio-frequency tumor ablation in the thorax.

Damian E Dupuy1, William W Mayo-Smith, Gerald F Abbott, Thomas DiPetrillo.   

Abstract

Minimally invasive alternatives to surgery for the treatment of malignancy are becoming more attractive owing to improvements in technology, reduced morbidity and mortality, and the ability to provide treatment in an outpatient setting. Radio-frequency (RF) ablation has become the imaging-guided ablative method of choice because of its relatively low cost, its capability of creating large regions of coagulative necrosis in a controlled fashion, and its relatively low toxicity. RF ablation in the thorax involves the use of computed tomography (CT) to localize the tumor and determine the optimal approach. The size of the tumor determines whether a cluster of electrodes or a single electrode of a particular length will be used to perform the ablation. CT fluoroscopy aids in guiding placement of the electrode. In patients with non-small cell lung malignancy who are not candidates for surgery owing to poor cardiorespiratory reserve, RF ablation alone or followed by conventional radiation therapy with or without chemotherapy may prove to be a treatment option. In patients with metastatic disease, RF ablation may be suitable for treatment of a small tumor burden or for palliation of larger tumors that cause symptoms such as cough, hemoptysis, or pain. Patients with chest wall or osseous metastatic tumors in whom other therapies have failed may benefit from RF ablation as an alternative to radiation therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12376615     DOI: 10.1148/radiographics.22.suppl_1.g02oc03s259

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  31 in total

1.  [Laser therapy of the lung: biophysical background].

Authors:  V Knappe; A Mols
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

Review 2.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

Review 3.  The role of percutaneous image-guided ablation for lung tumors.

Authors:  Elena N Petre; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Radiol Med       Date:  2014-07-01       Impact factor: 3.469

Review 4.  Common complications of nonvascular percutaneous thoracic interventions: diagnosis and management.

Authors:  Azzam Khankan; Shireen Sirhan; Fadi Aris
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 5.  Alternative to surgery in early stage NSCLC-interventional radiologic approaches.

Authors:  Kyungmouk Steve Lee; Bradley B Pua
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 6.  Thermal ablation of stage I non-small cell lung carcinoma.

Authors:  Carol A Ridge; Stephen B Solomon; Raymond H Thornton
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 7.  Lung cancer ablation: complications.

Authors:  Takao Hiraki; Hideo Gobara; Hiroyasu Fujiwara; Hiroaki Ishii; Koji Tomita; Mayu Uka; Satoko Makimoto; Susumu Kanazawa
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

Review 8.  Lung cancer ablation: technologies and techniques.

Authors:  Erica S Alexander; Damian E Dupuy
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

9.  Primary lung cancer: treatment with radio-frequency thermal ablation.

Authors:  L Thanos; S Mylona; M Pomoni; V Kalioras; L Zoganas; N Batakis
Journal:  Eur Radiol       Date:  2003-12-10       Impact factor: 5.315

10.  Radiofrequency ablation of lung tumors in swine assisted by a navigation device with preprocedural volumetric planning.

Authors:  Filip Banovac; Patrick Cheng; Enrique Campos-Nanez; Bhaskar Kallakury; Teo Popa; Emmanuel Wilson; Hernan Abeledo; Kevin Cleary
Journal:  J Vasc Interv Radiol       Date:  2009-11-25       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.